License Agreements - Narrative (Details) |
3 Months Ended | |||
|---|---|---|---|---|
|
Dec. 20, 2024
USD ($)
|
Dec. 19, 2024
USD ($)
d
|
Mar. 31, 2026
USD ($)
|
Mar. 31, 2025
USD ($)
|
|
| Capitalized Contract Cost [Line Items] | ||||
| Royalties on net product sales | $ 0 | $ 500,000 | ||
| BMSLicenseAgreement | ||||
| Capitalized Contract Cost [Line Items] | ||||
| Payments related to milestone | $ 0 | $ 0 | ||
| WuXi Biologics License Agreement | ||||
| Capitalized Contract Cost [Line Items] | ||||
| Non-refundable partial upfront payment | $ 6,000,000 | |||
| Additional non-refundable upfront payment | $ 38,000,000 | |||
| Number of days due with in effective date of license agreement | d | 120 | |||
| Aggregate payment of achievement of certain development milestone | $ 265,000,000 | |||
| Aggregate payment of achievement of certain commercial milestone | $ 540,000,000 | |||
| License agreement term | 10 years | |||